Patients Now Have the Option to Undergo Immunotherapy Less Frequently – Curetoday.com
|
Patients Now Have the Option to Undergo Immunotherapy Less Frequently
Curetoday.com The Food and Drug Administration (FDA) has approved a supplemental biologics license application adding a four-week dosing schedule for Opdivo (nivolumab) across several of the PD-1 inhibitor's indications. PUBLISHED March 06, 2018. The Food and Drug … |
